Hi, I'm the CellCarta AI Assistant. Ask me anything about our services.
Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)
AffichesMar 3, 2026
Oncologie
|
PCR
March 3, 2026
Pierre Gontard1, Nathalie Bernard1, Sara Diels1, Bart Tegenbos1, Dirk Goossens1, Lien Heyrman1, Magdalena Stolarek-Januszkiewicz2, Sam Abujudeh2, Jurgen Del Favero1,Barnaby Balmforth2
One global CRO for your whole therapeutic development journey
CellCarta has the multi-modal capabilities, scientific depth, and harmonized global footprint needed to advance even the most complex programs in precision medicine.
